drugset / Trial / NCT05268172
IFN-γ Combined With T Cells in the Treatment of Refractory Malignant Pleural Effusion and Ascites
Phase 1
Unknown
40 enrolled
Affiliated Hospital of Jiangnan University
Hunan Cancer Hospital · collabShenzhen Second People's Hospital · collabSichuan University · collabWest China Hospital · collabWuxi People's Hospital · collabZhejiang Provincial People's Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study was to evaluate the efficacy of IFN- Y combined with T cells in the treatment of refractory malignant pleural effusion and acties, using a multicenter, single-arm, open design.
Timeline
- Start
- 2022-12-20
- Primary completion
- 2024-12-30
- Completion
- 2025-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAR-T cells | Cell therapy | — | — |
| Subject | CIK cells | Cell therapy | 1e+09 cells | — |
| Subject | CIK cells | Cell therapy | 2e+09 cells | — |
| Subject | IFN-γ | Unknown | 5 ng/ml | — |
| Subject | Tcm cells | Cell therapy | — | — |